scholarly journals Decreased expression of LKB1 predicts poor prognosis in pancreatic neuroendocrine tumor patients undergoing curative resection

2018 ◽  
Vol Volume 11 ◽  
pp. 1259-1265
Author(s):  
Dezhi Li ◽  
Yu Zhou ◽  
Yanhui Liu ◽  
Ye Lin ◽  
Min Yu ◽  
...  
Keyword(s):  
Neuroendocrine Tumor ◽  
Poor Prognosis ◽  
Curative Resection ◽  
Pancreatic Neuroendocrine Tumor ◽  
Tumor Patients

Activity of Sunitinib in Patients With Advanced Neuroendocrine Tumors

2008 ◽  
Vol 26 (20) ◽  
pp. 3403-3410 ◽  
Author(s):  
Matthew H. Kulke ◽  
Heinz-Josef Lenz ◽  
Neal J. Meropol ◽  
James Posey ◽  
David P. Ryan ◽  
...  
Keyword(s):  
Growth Factor ◽  
Tyrosine Kinase ◽  
Neuroendocrine Tumor ◽  
Neuroendocrine Tumors ◽  
Objective Response ◽  
Pancreatic Neuroendocrine Tumor ◽  
Endocrine Tumor ◽  
Pancreatic Endocrine Tumor ◽  
Tumor Patients ◽  
Patient Reported

Purpose Standard cytotoxic chemotherapy has limited efficacy in metastatic neuroendocrine tumor patients. Neuroendocrine tumors express vascular endothelial growth factor (VEGF) and its receptor (VEGFR). Sunitinib malate, an oral tyrosine kinase inhibitor, has activity against VEGFRs as well as platelet-derived growth factor receptors, stem-cell factor receptor, glial cell line–derived neurotrophic factor, and FMS-like tyrosine kinase-3. We evaluated the efficacy of sunitinib in a two-cohort, phase II study of advanced carcinoid and pancreatic neuroendocrine tumor patients. Patients and Methods Patients were treated with repeated 6-week cycles of oral sunitinib (50 mg/d for 4 weeks, followed by 2 weeks off treatment). Patients were observed for response, survival, and adverse events. Patient-reported outcomes were assessed. Results Among 109 enrolled patients, 107 received sunitinib (carcinoid, n = 41; pancreatic endocrine tumor, n = 66). Overall objective response rate (ORR) in pancreatic endocrine tumor patients was 16.7% (11 of 66 patients), and 68% (45 of 66 patients) had stable disease (SD). Among carcinoid patients, ORR was 2.4% (one of 41 patients), and 83% (34 of 41 patients) had SD. Median time to tumor progression was 7.7 months in pancreatic neuroendocrine tumor patients and 10.2 months in carcinoid patients. One-year survival rate was 81.1% in pancreatic neuroendocrine tumor patients and 83.4% in carcinoid patients. No significant differences from baseline in patient-reported quality of life or fatigue were observed during treatment. Conclusion Sunitinib has antitumor activity in pancreatic neuroendocrine tumors; its activity against carcinoid tumors could not be definitively determined in this nonrandomized study. Randomized trials of sunitinib in patients with neuroendocrine tumors are warranted.

scholarly journals High Expression of MicroRNA-196a Indicates Poor Prognosis in Resected Pancreatic Neuroendocrine Tumor

Medicine ◽  
2015 ◽  
Vol 94 (50) ◽  
pp. e2224 ◽  
Author(s):  
Yoon Suk Lee ◽  
Haeryoung Kim ◽  
Hyoung Woo Kim ◽  
Jong-Chan Lee ◽  
Kyu-Hyun Paik ◽  
...  
Keyword(s):  
Neuroendocrine Tumor ◽  
Poor Prognosis ◽  
Pancreatic Neuroendocrine Tumor ◽  
High Expression

scholarly journals Impact of perioperative blood transfusion on survival in pancreatic neuroendocrine tumor patients: analysis from the US Neuroendocrine Study Group

HPB ◽  
2020 ◽  
Vol 22 (7) ◽  
pp. 1042-1050
Author(s):  
Paula Marincola Smith ◽  
Jordan Baechle ◽  
Carmen C. Solórzano ◽  
Marcus Tan ◽  
Alexandra G. Lopez-Aguiar ◽  
...  
Keyword(s):  
Blood Transfusion ◽  
Neuroendocrine Tumor ◽  
Pancreatic Neuroendocrine Tumor ◽  
Study Group ◽  
Tumor Patients ◽  
The Us ◽  
Perioperative Blood Transfusion

Metformin with everolimus and octreotide in pancreatic neuroendocrine tumor patients with diabetes

2016 ◽  
Vol 12 (10) ◽  
pp. 1251-1260 ◽  
Author(s):  
Sara Pusceddu ◽  
Roberto Buzzoni ◽  
Claudio Vernieri ◽  
Laura Concas ◽  
Sara Marceglia ◽  
...  
Keyword(s):  
Neuroendocrine Tumor ◽  
Pancreatic Neuroendocrine Tumor ◽  
Tumor Patients ◽  
Patients With Diabetes

scholarly journals CD47 expression and CD163+ macrophages correlated with prognosis of pancreatic neuroendocrine tumor

BMC Cancer ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Rami Imam ◽  
Qing Chang ◽  
Margaret Black ◽  
Caroline Yu ◽  
Wenqing Cao
Keyword(s):  
Lymph Node ◽  
Lymph Node Metastasis ◽  
Neuroendocrine Tumor ◽  
Poor Prognosis ◽  
Lymphovascular Invasion ◽  
Perineural Invasion ◽  
Pancreatic Neuroendocrine Tumor ◽  
Node Metastasis ◽  
Well Differentiated ◽  
Lower Expression

Abstract Background Recent studies have suggested the important roles of CD47 and tumor-associated macrophages in the prognosis and immunotherapy of various human malignancies. However, the clinical significance of CD47 expression and CD163+ TAMs in pancreatic neuroendocrine tumor (PanNET) remains unclear. Methods In this study, 47 well-differentiated PanNET resection specimens were collected. CD47 expression and CD163+ macrophages were evaluated using immunohistochemistry and correlated with clinicopathologic properties. Results Positive CD47 staining was seen in all PanNETs as well as adjacent normal islets. Compared to normal islets, CD47 overexpressed in PanNETs (p = 0.0015). In the cohort, lymph node metastasis (LNM), lymphovascular invasion (LVI), and perineural invasion (PNI) were found in 36.2, 59.6, and 48.9% of the cases, respectively. Interestingly, PanNETs with LNM, LVI, or PNI had significantly lower H-score of CD47 than those without LNM (p = 0.035), LVI (p = 0.0005), or PNI (p = 0.0035). PanNETs in patients with disease progression (recurrence/death) also showed a significantly lower expression of CD47 than those without progression (p = 0.022). In contrast, CD163+ macrophage counts were significantly higher in cases with LNM, LVI, and PNI. Conclusions Our data suggest relative low CD47 expression and high CD163+ TAMs may act as indicators for poor prognosis of PanNETs.

ALCAM (CD166) Expression as Novel Prognostic Biomarker for Pancreatic Neuroendocrine Tumor Patients

2011 ◽  
Vol 170 (2) ◽  
pp. 226-232 ◽  
Author(s):  
Michael Tachezy ◽  
Hilke Zander ◽  
Andreas H. Marx ◽  
Florian Gebauer ◽  
Tamina Rawnaq ◽  
...  
Keyword(s):  
Neuroendocrine Tumor ◽  
Prognostic Biomarker ◽  
Pancreatic Neuroendocrine Tumor ◽  
Tumor Patients
Sign in / Sign up

Export Citation Format

Share Document